Non-Hodgkin's Lymphoma Articles

FDA Grants Tisagenlecleucel Priority Review for DLBCL
The FDA has granted a priority review to the CAR T-cell therapy tisagenlecleucel for adult patients with relapsed/refractory DLBCL who are ineligible for or relapse after autologous stem cell transplant. 
Axi-Cel Plus Atezolizumab Active, Safe in DLBCL
The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.
Frontline Lenalidomide/Rituximab Combo Warrants Further Investigation in MCL
Jia Ruan, MD, PhD, discusses the pivotal analysis of the combination of lenalidomide plus rituximab, as well as the next steps for this regimen in the field of mantle cell lymphoma.
Combination Therapies Poised to Improve CLL Treatment Landscape
Aaron Logan, MD, PhD, discusses the most promising combinations and available treatments for patients with chronic lymphocytic leukemia.
Venetoclax Demonstrates Strong Activity in CLL After BCR Inhibitor
Patients with relapsed/refractory CLL who failed on previous treatment with a BCR signaling pathway inhibitor had an overall response rate of 65% following treatment with venetoclax (Venclexta).
Long-Term Ibrutinib Follow-up Demonstrates Continued Efficacy in MCL
More than one-quarter of patients with relapsed/refractory mantle cell lymphoma remained progression free and nearly half were alive at 3 years when treated with the BTK inhibitor ibrutinib (Imbruvica). 
Rituximab/Lenalidomide Regimen Misses Endpoint in Phase III Follicular Lymphoma Study
The combination of rituximab and lenalidomide followed by maintenance therapy with the same regimen did not improve response nor progression-free survival compared with rituximab and chemotherapy with rituximab maintenance for patients with previously untreated follicular lymphoma.
NICE Recommends Ibrutinib for Relapsed/Refractory MCL
The United Kingdom's National Institute for Health Care and Excellence has published new guidelines recommending ibrutinib as treatment for patients with relapsed/refractory mantle cell lymphoma.
Update Shows Frontline Bendamustine/Rituximab Improves TTNT in NHL
Ten-year follow-up results from the StiL NHL1 study showed that frontline bendamustine (Treanda) plus rituximab (Rituxan) improved time-to-next-treatment compared with CHOP-R in patients with indolent lymphomas.
Promising Results in CLL for Frontline Ibrutinib Plus Chemoimmunotherapy
Adding ibrutinib to a standard frontline chemoimmunotherapy for chronic lymphocytic leukemia induced negative minimum residual disease status in bone marrow for 83% of patients.
Publication Bottom Border
Border Publication